Bogotá based Tarkus Pharma Lab, with production facilities in Tocancipá, north of the capital, has announced that it has obtained INVIMA certification with the endorsement of Good Manufacturing Practices (GMP), allowing the manufacture of phyto-therapeutic products derived from cannabis for commercial use and with export potential. INVIMA (Instituto Nacionál de Vigilancia de Medicamentos y Alimentos) is Colombia’s food and drug regulatory agency.
Tarkus says it is looking for a local partner to enter the US market to distribute its high quality products at attractive market prices.
Currently, the company has cannabis-derived raw materials, standardized mixtures and magistral formulas. By obtaining the certification, the laboratory is authorized to produce finished phyto-therapeutic products (ingestible products for medicinal purposes from natural origin).
“To achieve this important step, we have the required investment and a team of experts in the pharmaceutical industry. Additionally, we will place our products in pharmacies and department stores, facilitating access to thousands of people with chronic pathologies, so that they can enjoy the benefits offered by cannabis-based products,” said Alejandro Venegas, CEO of Tarkus.
Although the export of raw material does not require INVIMA certification, it is a requirement for the commercialization of the final labeled product that reaches consumers.